Biological Psychiatry (journal)

Gate Neurosciences to Share New Data and Research Insights on its Synaptic Function Molecules with Multiple Posters at 2024 ASCP Annual Meeting

Retrieved on: 
星期三, 五月 15, 2024
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, CSF, NMDAR, Poster, NMDA, Biological Psychiatry (journal), Society, Psychiatry, LTP, Annual general meeting, CNS, Biomarker, Quantitative electroencephalography, Medicine, ASCP, Gate, Neuroscience, Pharmaceutical industry

The company will present new preclinical and clinical data supporting its NMDAR PAM portfolio and will share novel insights from internal research on the biological mechanisms of neuroplasticity and synaptic function.

Key Points: 
  • The company will present new preclinical and clinical data supporting its NMDAR PAM portfolio and will share novel insights from internal research on the biological mechanisms of neuroplasticity and synaptic function.
  • Specifically, Gate Neurosciences will highlight its cutting-edge research on how a single dose of neuroplasticity-enhancing drugs can trigger both rapid-onset (i.e.
  • Gate Neurosciences 3rd Annual R&D Day at ASCP 2024:
    “Over the past few years, the Gate team has made considerable progress in understanding mechanisms that rapidly and durably enhance synaptic function for treating CNS diseases.
  • Key takeaways include:
    Full abstracts will be published by ASCP following the conclusion of the 2024 Annual Meeting.

4M Therapeutics Presented Novel Preclinical Data at SOBP Annual Meeting 2024 Demonstrating Potent Effects of Inhibitors of GSK3β for the Treatment of Bipolar Disorder

Retrieved on: 
星期一, 五月 13, 2024
Research, Mental Health, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Patient, Amphetamine, Shikimate pathway, Lithium, Therapy, Safety, Biological Psychiatry (journal), Society, AMP, USV, DSM-IV codes, Poster, Brain, Bipolar disorder, Standard of care, Annual general meeting, Pharmaceutical industry

The poster, titled “The Effects of Novel Small Molecules in a Preclinical Model of Positive Affective State,” was presented on May 11, 2024.

Key Points: 
  • The poster, titled “The Effects of Novel Small Molecules in a Preclinical Model of Positive Affective State,” was presented on May 11, 2024.
  • “Our presentation underscored the capability of our novel small molecules to selectively target GSK3β and demonstrate efficacy for the treatment of bipolar disorder and acute mania,” said Dr. Pablo Lapuerta, Chief Executive Officer and Co-Founder of 4M Therapeutics.
  • Similar patterns were observed across USV categories and treatment groups in both the first and second hour after AMP dosing.
  • In addition, supporting data showed target engagement for 4MT-A through the reduction of pCRMP2 in vitro in excitatory cortical neurons and in vivo in rat brain.

Delix Announces DLX-001 Demonstrates Evidence of CNS Penetration and Brain Activity Without Psychotomimetic, Dissociative, or Hallucinogenic Effects in Ongoing Phase 1 Trial

Retrieved on: 
星期一, 五月 13, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Patient, Pharmacokinetics, CSF, Dissociative, SAD, EEG, Ketamine, MDD, DMT, Therapy, Safety, Food, Biological Psychiatry (journal), MD, Hallucination, Cardiotoxicity, Quantitative electroencephalography, Psychiatry, DSM-IV codes, Cerebrospinal fluid, Vivo, Society, ASCP, Psilocybin, CHDR, Pharmaceutical industry

The Company also announced preclinical data showing the effects of DLX-001 on antidepressant, structural, and functional plasticity assays.

Key Points: 
  • The Company also announced preclinical data showing the effects of DLX-001 on antidepressant, structural, and functional plasticity assays.
  • Part B is an open-label crossover design study to investigate the effect of food on the PK of DLX-001.
  • No psychotomimetic, hallucinatory, or dissociative effects have been observed, as reflected by no change over time on a robust battery of assessments.
  • DLX-001 exhibited both rapid—within 24-hours, and enduring—up to 14 days, antidepressant-like activity after a single dose in multiple behavioral models.

Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, Annual general meeting, Therapy, Port, Somnolence, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry (SOBP) Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • Our proprietary Glyph™ platform allows SPT-300 to be absorbed like a dietary fat through the intestinal lymphatic system and transported into circulation.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences

Retrieved on: 
星期四, 五月 9, 2024
Neurology, Mental Health, Health, Pharmaceutical, Clinical Trials, Schizophrenia, CMO, Neuroscience, University of Toronto, University of California, Cognition, Vortioxetine, Biological Psychiatry (journal), Biomarker, Prevalence, Into, Diagnosis, Deficit spending, Drug development, Area studies, Remind, Depression, Data, Pharmacodynamics, EEG, Bipolar, Trial, Chair, Volunteering, Lab, Cognitive deficit, Doctor of Philosophy, Society, University, Cyclothymia, Randomness, ASCP, Pharmaceutical industry

“Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.

Key Points: 
  • “Alto’s precision psychiatry platform continues to get stronger with each new dataset we analyze.
  • Importantly, we have systematically identified and prospectively replicated neurobiological markers linked to cognitive impairment associated with schizophrenia in a comprehensive analysis inclusive of all major candidate biomarkers.
  • New analysis of vortioxetine Phase 3 data demonstrates that baseline cognitive performance is not a moderator of response to vortioxetine.
  • A notable relationship between theta response and processing speed, which is thought to underpin cognitive impairment in schizophrenia, was observed.

PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Retrieved on: 
星期四, 五月 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, TSST, Society, Lymphatic system, Safety, Randomness, Pharmacokinetics, Lymph, Neuropsychiatry, Depression, Neurosteroid, Trier social stress test, Human, GABAA, Anxiety, Biological Psychiatry (journal), Trier, Patient, PRTC, Annual general meeting, Therapy, Somnolence, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics , a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX.
  • “These data summarize some of the evidence supporting the core mechanisms of SPT-300 as we advance to later-stage clinical studies.
  • The most common treatment-emergent adverse event was somnolence (29% SPT-300 vs. 13% placebo), which was transient and mild or moderate.
  • SPT-300 was generally well-tolerated and demonstrated GABA modulatory pharmacological activity that merits further investigation in stress-related mood and anxiety disorders, including anxious depression.

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期四, 三月 7, 2024
DSM-IV codes, Research, Type D, Biological Psychiatry (journal), FDA, Food, Schizophrenia, Vortioxetine, PAM, Aggression, Annual general meeting, Society, IPR, Safety, Therapy, Patient, MDD, Pharmaceutical industry

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • In October 2023, Neumora announced that Robert Lenz, M.D., Ph.D., had joined Neumora as executive vice president, head of R&D.
  • Cash Position: As of December 31, 2023, Neumora had cash, cash equivalents and marketable securities of $463.8 million.
  • R&D Expense: Research and development expenses for the fourth quarter of 2023 were $38.9 million, as compared to $23.5 million for the same period in 2022.
  • Net Loss: The Company reported a net loss of $108.7 million for the fourth quarter of 2023, as compared to $28.1 million for the same period in 2022.

Yale School of Medicine Expert to Receive International Mental Health Prize for Ketamine Antidepressant Discovery

Retrieved on: 
星期五, 十月 6, 2023
National Academy of Medicine, Neuroscience, Multimedia, Food, Doctor of Philosophy, Biological Psychiatry (journal), Yale school, NAM, MD, Translational research, Organization, Krystal, Ketamine, National academy, Psychiatry, FDA, Mental health, Food and Drug Administration, Yale School of Medicine, Depression, Psychology, Patient, Pharmaceutical industry, Yale University, Esketamine, HAVEN

International mental health prize from the National Academy of Medicine goes to a Yale ketamine expert and colleagues.

Key Points: 
  • International mental health prize from the National Academy of Medicine goes to a Yale ketamine expert and colleagues.
  • They are being honored for their discovery of the rapid antidepressant effects of ketamine and the identification of its efficacy for treatment-resistant depression.
  • That discovery led to the development of the antidepressant Esketamine, the first mechanistically novel U.S. Food and Drug Administration (FDA)-approved antidepressant in over 50 years.
  • It is awarded annually to individuals, groups, or organizations that have demonstrated outstanding achievement in improving mental health.

Sahmyook University Researchers Identify Genes Associated with Addiction to Psychostimulant Drugs

Retrieved on: 
星期三, 八月 30, 2023
Arc, COC, Life, Methamphetamine, Brain, Attention, Psychological abuse, Messenger, Assistant, WT, Cocaine, Biological Psychiatry (journal), Nervous system, Sahmyook University, Mouse, Observation, Gene, Addiction, Drug, Pharmaceutical industry, Vaccine, PER2

Per2 is associated with our circadian rhythms, our internal clock which regulates our sleep-wake cycle.

Key Points: 
  • Per2 is associated with our circadian rhythms, our internal clock which regulates our sleep-wake cycle.
  • However, its addictive responses to METH and other psychostimulant drugs like cocaine have not been examined as yet.
  • The researchers first investigated the motivational effect of these drugs and their impact on the locomotor activity of the mice using specialized tests.
  • Using existing data, the researchers could correlate these genes with those that are activated in the region of the brain that responds to drug addiction.

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

Retrieved on: 
星期四, 五月 11, 2023
Well, Consensus, Psilocybin, Acceleration, PK, Insurance, GABA, DMT, Society, MCCB, PD, IV, D&O, Benzodiazepine, OTF, VAT, Anorexia nervosa, COMP, PTSD, G&A, Part, Accounting, Anxiety disorder, Patient, Investment, Administration, EEG, Biological Psychiatry (journal), Annual general meeting, Pivotal, CIAS, Entrepreneurship, Oxygen toxicity, Research and development, Research, R, TRD, Safety, Cognitive deficit, Pharmaceutical industry, Palladium, Bank, Surveying, Schizophrenia

The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.

Key Points: 
  • The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.
  • NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates.
  • “This past quarter we made significant progress, including the dosing of the first patient with RL-007 in a randomized, placebo-controlled Phase 2 study.
  • In January 2023, Phase 1 results were announced from the study of GRX-917 in healthy volunteers.